$32.45
+1.04 (+3.31%)
Open$32.25
Previous Close$31.41
Day High$34.34
Day Low$31.51
52W High$51.93
52W Low$29.24
Volume—
Avg Volume528.2K
Market Cap1.65B
P/E Ratio99.65
EPS$0.26
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+34.4% upside
Current
$32.45
$32.45
Target
$43.60
$43.60
$27.22
$43.60 avg
$49.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 253.55M | 213.27M | 156.14M |
| Net Income | 15.16M | 11.48M | 35.53M |
| Profit Margin | 6.0% | 5.7% | 22.8% |
| EBITDA | 20.69M | 16.53M | 44.60M |
| Free Cash Flow | — | — | 32.60M |
| Rev Growth | +18.9% | +18.9% | +24.7% |
| Debt/Equity | 0.01 | 0.01 | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |